The team at CBD.fr has transcribed the article from MARIJUANA DAILY BUSINESS into French for your convenience… you will find the original article written byAlfredo Pascual
Argentine authorities have published a new decree aimed at addressing the shortcomings of the regulations governing the medical cannabis sector in the country, which have largely failed to materialize since the initial law and decree were approved in 2017.
The new decree replaces the 2017 version, which did not facilitate significant access to medical cannabis and, by extension, opportunities for businesses.
Gif of a cannabis farm
The new decree allows pharmacies to dispense compounded cannabis preparations.
It broadens the scope of the law by allowing, in principle, access to medical cannabis for any medical condition—not just refractory epilepsy, as was the case with the 2017 version of the regulation.
One of the goals of the new decree is to facilitate subsidized access to cannabis derivatives for patients with a “medical indication.”
The updated decree includes a series of objectives that somewhat overlap with those of the 2017 version, including research-focused goals.
The decree acknowledges that “regulatory restrictions” have hindered access to medical cannabis.
In its introduction, the new decree notes that regulations have thus far only allowed individuals with refractory epilepsy to effectively access cannabis products, but the products have been out of reach for most patients due to the high cost of importing them.
Both the 2017 law and the decree also listed a goal of providing free medical cannabis to patients in the program.
This has simply never materialized in any meaningful way.
